Jason Lettmann
CIK 1688269 · CHIEF EXECUTIVE OFFICER · last filed 2026-03-23
Jason Lettmann is a CHIEF EXECUTIVE OFFICER who has filed 24 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing shows the insider sold $26.7K of ALXO on Mar 23, 2026. Across all open-market trades the lifetime net is −$764.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.66M
2
24
-$764.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALXO | CHIEF EXECUTIVE OFFICER | 2,317,078 | $1.58 | $3.66M | -$5.88M | 22 | 2026-03-23 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | 2,482,308 | — | — | $5.12M | 2 | 2017-06-22 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-23 | ALXO | Sell (S) | −12,311 | -$26.7K | EDGAR |
| 2026-02-19 | ALXO | Tax (F) | −2,201 | -$5.0K | EDGAR |
| 2026-01-28 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2025-10-16 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2025-09-18 | ALXO | Buy (P) | +92,233 | $99.4K | EDGAR |
| 2025-08-19 | ALXO | Sell (S) | −2,382 | -$1.5K | EDGAR |
| 2025-04-15 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2025-03-18 | ALXO | Grant (A) | +42,000 | $0 | EDGAR |
| 2025-02-21 | ALXO | Sell (S) | −2,159 | -$2.5K | EDGAR |
| 2025-01-23 | ALXO | Grant (A) | — | $0 | EDGAR |